Skip to main content

formoterol

Generic: FORMOTEROL FUMARATE·Brand: FORADIL, FORADIL CERTIHALER, FORMOTEROL FUMARATE, PERFOROMIST

formoterol: developed by 2 companies · 1 clinical trial tracked · 2 FDA decisions.

formoterol evidence translation

What we can confirm

2 FDA records · 1 tracked trial

What it means

More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

What is verified about formoterol, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

Development Pipeline (2)
CompanyPhase
Novartis AG (NVS)Approved
Viatris Inc (VTRS)Approved
Clinical Trials (1)

Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD): A Phase IV, Prospective, Randomized, Blinded, Parallel-group Trial

NCT07721922·Phase 4
Not yet recruiting

Primary endpoint: Difference in Modified Borg Dyspnea Scale scores between groups

InterventionalRandomizedtriple280 targetStarted 2026-09Completion 2028-091 site · United StatesUniversity of Tennessee Graduate School of Medicine
FDA Decisions2 records
Approval1 INDICATIONS AND USAGE Formoterol fumarate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: • Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ( 1.1 ) Important limitations of use: • Formoterol fumarate inhalation solution is not indicated to treat acute deteriorations of chronic (VTRS)FDA ↗
NDA022007Type 3 - New Dosage FormStandardInhalationSolution
Approval(NVS)FDA ↗
NDA021592Type 3 - New Dosage FormStandardInhalationPowder

Frequently asked questions

Who is developing formoterol?

formoterol is being developed by Novartis AG, Viatris Inc.

How many clinical trials involve formoterol?

BioSniper tracks 1 clinical trial involving formoterol.

What is formoterol's latest FDA decision?

The most recent tracked FDA decision for formoterol is Approval for 1 INDICATIONS AND USAGE Formoterol fumarate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: • Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ( 1.1 ) Important limitations of use: • Formoterol fumarate inhalation solution is not indicated to treat acute deteriorations of chronic , dated May 11, 2007.